Abstract
Antibodies have become one of the dominant therapeutic platforms due to their safety, specificity, and efficacy. Owing to their massive potential diversity intrinsic to their structure, the number of possible different molecules that could be generated and analyzed from natural or synthetic systems is almost limitless. However, even with vast improvements in automation, classic antibody generation and analysis systems are severely limited in the number of molecules that can be interrogated during a typical discovery campaign. When one considers more complex target systems, along with the desire to isolate antibodies with very unique characteristics, the chances are very low that these systems will be successful. Next generation sequencing technologies (also referred to as “deep sequencing”) allow for the analysis of single molecules in millions in a very short period of time. By applying these deep sequencing technologies to antibody discovery, we now have the ability to look for very specific molecules with very unique properties and activities, further our understanding of species and strain specific repertoires, and can now begin to use sequence information to identify function. The application of these technologies is opening the door to the discovery of next generation antibody therapeutics.
Keywords: Antibody discovery, biotherapeutic, deep sequencing, diversity, phage display, rodent immunization.
Current Drug Discovery Technologies
Title:Deep Sequencing Approaches to Antibody Discovery
Volume: 11 Issue: 1
Author(s): Michael F. Naso, Jin Lu and Tadas Panavas
Affiliation:
Keywords: Antibody discovery, biotherapeutic, deep sequencing, diversity, phage display, rodent immunization.
Abstract: Antibodies have become one of the dominant therapeutic platforms due to their safety, specificity, and efficacy. Owing to their massive potential diversity intrinsic to their structure, the number of possible different molecules that could be generated and analyzed from natural or synthetic systems is almost limitless. However, even with vast improvements in automation, classic antibody generation and analysis systems are severely limited in the number of molecules that can be interrogated during a typical discovery campaign. When one considers more complex target systems, along with the desire to isolate antibodies with very unique characteristics, the chances are very low that these systems will be successful. Next generation sequencing technologies (also referred to as “deep sequencing”) allow for the analysis of single molecules in millions in a very short period of time. By applying these deep sequencing technologies to antibody discovery, we now have the ability to look for very specific molecules with very unique properties and activities, further our understanding of species and strain specific repertoires, and can now begin to use sequence information to identify function. The application of these technologies is opening the door to the discovery of next generation antibody therapeutics.
Export Options
About this article
Cite this article as:
Naso F. Michael, Lu Jin and Panavas Tadas, Deep Sequencing Approaches to Antibody Discovery, Current Drug Discovery Technologies 2014; 11 (1) . https://dx.doi.org/10.2174/15701638113106660040
DOI https://dx.doi.org/10.2174/15701638113106660040 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Formaldehyde the Missing Link in AD Pathology? The Differential Aggregation of Amyloid-Beta with APOE Isoforms In Vitro
Current Alzheimer Research Categorization & Recognition of Lung Tumor Using Machine Learning Representations
Current Medical Imaging Novel Agents in Anticancer Drug Therapy I (Antiangiogenic Agents, Egfr Inhibitors)
Medicinal Chemistry Reviews - Online (Discontinued) Pathological Brain Image Segmentation and Classification: A Survey
Current Medical Imaging Mitochondria, Cellular Stress Resistance, Somatic Cell Depletion and Lifespan
Current Aging Science Mechanism of Action of Flavonoids in Prevention of Inflammation- Associated Skin Cancer
Current Medicinal Chemistry Understanding the Cardiovascular Actions of Soy Isoflavones: Potential Novel Targets for Antihypertensive Drug Development
Cardiovascular & Hematological Disorders-Drug Targets Review of Cell and Organ Printing Patents
Recent Patents on Biomedical Engineering (Discontinued) Heteroaromatization with 4-Phenyldiazenyl-1-naphthol. Part IV: Synthesis of Some New Heterocyclic Compounds with Potential Biological Activity
Current Organic Synthesis Synthesis of N-glycosylated Dihydropyrimidones – A Novel Approach Using Epoxy Sugar
Letters in Organic Chemistry Recent Advances of Chitosan and its Derivatives in Biomedical Applications
Current Medicinal Chemistry Formation and Structure of a Novel Nitration Product of δ -Tocopherol
Current Organic Synthesis Occurrence, Structure Elucidation, Biosynthesis, Functions and Synthesis of Sphingadienes
Mini-Reviews in Organic Chemistry QSAR by Minimal Topological Difference[s]: Post-Modern Perspectives
Current Medicinal Chemistry Patents and the Development on Polymer based Nanomaterial (PAMAM Dendrimer) for Biomedical Applications
Recent Patents on Biomedical Engineering (Discontinued) Synthesis of 9-O-3-(1-piperazinyl/morpholinyl/piperidinyl)pentyl-berberines as Potential Antioxidant and Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Preparation and Optimization of Moxifloxacin Microspheres for Colon Targeted Delivery Using Quality by Design Approach: In Vitro and In Vivo Study
Current Drug Delivery Mini Heme-Proteins: Designability of Structure and Diversity of Functions
Current Protein & Peptide Science Biotransformation of Endocrine Disrupting Compounds by Selected Phase I and Phase II Enzymes – Formation of Estrogenic and Chemically Reactive Metabolites by Cytochromes P450 and Sulfotransferases
Current Medicinal Chemistry Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2
Current Drug Metabolism